Andreas Krebs - 11 Jun 2026 Form 4 Insider Report for Definium Therapeutics, Inc. (DFTX)

Reporting relationship: Director
Issuer ticker: DFTX
Reported as of: 11 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Jun 2026, 16:30:14 UTC
Prior SEC filing: 16 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Mark Sullivan, Attorney-in-Fact for Andreas Krebs

Key filing fact

Andreas Krebs filed Form 4 for Definium Therapeutics, Inc. (DFTX) on 15 Jun 2026.

Key facts

This page summarizes Andreas Krebs's Form 4 filing for Definium Therapeutics, Inc. (DFTX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 15 Jun 2026, 16:30.

Change

Previous filing in this sequence was filed on 16 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001438946 Primary reporting owner

Krebs Andreas

Relationship: Director
Address: C/O DEFINIUM THERAPEUTICS, INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK
Signature: /s/ Mark Sullivan, Attorney-in-Fact for Andreas Krebs
Signature date: 15 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DFTX transaction

Common Shares

Award

Transaction value
Shares: +4,666
Change %: +31%
Price: $0.000000^*
Shares after: 19,773
Date: 11 Jun 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DFTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +19,188
Change %
Price: $0.000000^*
Shares after: 19,188
Date: 11 Jun 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 19,188
Exercise price: $24.11
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date.

Footnote F2

The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date.